Jeffrey W. Albers Sells 5,000 Shares of Blueprint Medicines Corp (NASDAQ:BPMC) Stock

Share on StockTwits

Blueprint Medicines Corp (NASDAQ:BPMC) CEO Jeffrey W. Albers sold 5,000 shares of the stock in a transaction that occurred on Monday, June 17th. The stock was sold at an average price of $99.06, for a total value of $495,300.00. Following the transaction, the chief executive officer now directly owns 33,961 shares in the company, valued at approximately $3,364,176.66. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.

Shares of NASDAQ BPMC traded down $1.03 during mid-day trading on Wednesday, hitting $96.77. The company had a trading volume of 689,723 shares, compared to its average volume of 466,875. The company has a market cap of $4.73 billion, a price-to-earnings ratio of -17.95 and a beta of 1.45. Blueprint Medicines Corp has a 12 month low of $44.58 and a 12 month high of $100.76. The company has a current ratio of 6.59, a quick ratio of 6.59 and a debt-to-equity ratio of 0.27.

Blueprint Medicines (NASDAQ:BPMC) last announced its quarterly earnings results on Thursday, May 9th. The biotechnology company reported ($1.98) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.83) by ($0.15). The company had revenue of $0.73 million during the quarter, compared to the consensus estimate of $1.38 million. Blueprint Medicines had a negative return on equity of 59.26% and a negative net margin of 603.88%. The company’s revenue for the quarter was down 23.2% on a year-over-year basis. During the same period last year, the business posted ($1.29) EPS. As a group, equities analysts forecast that Blueprint Medicines Corp will post -7.76 earnings per share for the current fiscal year.

BPMC has been the topic of a number of research analyst reports. BidaskClub downgraded Blueprint Medicines from a “strong-buy” rating to a “buy” rating in a report on Wednesday, March 6th. Wedbush reaffirmed an “outperform” rating on shares of Blueprint Medicines in a report on Tuesday, February 26th. Cowen reaffirmed a “buy” rating on shares of Blueprint Medicines in a report on Thursday, March 28th. Goldman Sachs Group reaffirmed a “buy” rating and set a $125.00 target price on shares of Blueprint Medicines in a report on Thursday, May 23rd. Finally, ValuEngine raised Blueprint Medicines from a “buy” rating to a “strong-buy” rating in a report on Tuesday, June 4th. Eight research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. The company currently has an average rating of “Buy” and an average price target of $105.83.

Several hedge funds and other institutional investors have recently made changes to their positions in BPMC. Hillhouse Capital Advisors Ltd. bought a new stake in Blueprint Medicines during the 4th quarter valued at $77,142,000. Norges Bank bought a new stake in Blueprint Medicines during the 4th quarter valued at $42,705,000. FMR LLC raised its stake in Blueprint Medicines by 5.3% during the 1st quarter. FMR LLC now owns 6,939,294 shares of the biotechnology company’s stock valued at $555,491,000 after acquiring an additional 346,738 shares in the last quarter. Foresite Capital Management III LLC raised its stake in Blueprint Medicines by 133.8% during the 4th quarter. Foresite Capital Management III LLC now owns 467,682 shares of the biotechnology company’s stock valued at $25,213,000 after acquiring an additional 267,682 shares in the last quarter. Finally, Marshall Wace North America L.P. bought a new stake in Blueprint Medicines during the 1st quarter valued at $21,105,000. 97.46% of the stock is currently owned by institutional investors and hedge funds.

COPYRIGHT VIOLATION NOTICE: “Jeffrey W. Albers Sells 5,000 Shares of Blueprint Medicines Corp (NASDAQ:BPMC) Stock” was reported by Ticker Report and is the property of of Ticker Report. If you are reading this story on another site, it was illegally copied and reposted in violation of US and international copyright & trademark laws. The correct version of this story can be accessed at https://www.tickerreport.com/banking-finance/4379902/jeffrey-w-albers-sells-5000-shares-of-blueprint-medicines-corp-nasdaqbpmc-stock.html.

About Blueprint Medicines

Blueprint Medicines Corporation develops drugs of small molecule kinase inhibitors that target genomic drivers in various cancers and a rare genetic disease. Its lead drug candidates include avapritinib, which completed Phase I clinical trials that targets PDGFRA Exon 18 mutant GIST and KIT-driven GIST; and BLU-554, which is in Phase I clinical trials an orally available, potent, and irreversible inhibitor of the kinase FGFR4 that is activated in a defined subset of patients with hepatocellular carcinoma.

Recommended Story: What is the price-to-earnings growth (PEG) ratio?

Insider Buying and Selling by Quarter for Blueprint Medicines (NASDAQ:BPMC)

Receive News & Ratings for Blueprint Medicines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Blueprint Medicines and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Omnicom Group  Set to Announce Earnings on Wednesday
Omnicom Group Set to Announce Earnings on Wednesday
Consolidated-Tomoka Land  Scheduled to Post Quarterly Earnings on Wednesday
Consolidated-Tomoka Land Scheduled to Post Quarterly Earnings on Wednesday
Kinder Morgan Canada  Scheduled to Post Earnings on Wednesday
Kinder Morgan Canada Scheduled to Post Earnings on Wednesday
Preferred Bank  to Release Quarterly Earnings on Wednesday
Preferred Bank to Release Quarterly Earnings on Wednesday
Kinder Morgan  Set to Announce Earnings on Wednesday
Kinder Morgan Set to Announce Earnings on Wednesday
Cohen & Steers  to Release Quarterly Earnings on Wednesday
Cohen & Steers to Release Quarterly Earnings on Wednesday


© 2006-2019 Ticker Report